Kazia CEO Dr James Garner says the company is looking for partners to assist in the next phase of Cantrixil’s development.
“The data unambiguously demonstrates the potential for Cantrixil to provide benefit in this very challenging patient population,” Dr Garner said.
”With this positive data in hand, our focus now shifts to partnering activity, and we hope to transition Cantrixil to a company which both shares our belief in its potential and is able to apply the necessary resources and expertise to realise that potential over the next chapter of its development,” he added.
KZA Price at posting:
$1.38 Sentiment: Buy Disclosure: Held
